Ryan J. Thimjon

Feltl and Company upgraded TearLab Corp (NASDAQ: TEAR) from Buy to Strong Buy Thursday and lowered its price target from $6.25 to $5. Analysts Ben C. Haynor and Ryan J. Thimjon believed “TearLab to be a unique medical technology company. There are few medical technology firms targeting a...